Olmesartan severely weakened the development of NASH in an animal model of hypercholesterolemia

Atherosclerosis

Volumn 216, Issue 1, 2011, Pages 97-102

  Sturzeneker, Mário Cláudio Soares ^a   Ioshii, Sergio Ossamu ^a   Baroncini, Liz Andréa Villela ^a   Précoma, Dalton Bertolim ^a  

^a PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Hepatic cirrhosis; Non alcoholic fatty liver disease; Olmesartan

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; OLMESARTAN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE COURSE; HEPATITIS; HISTOPATHOLOGY; HYPERCHOLESTEROLEMIA; LIVER FIBROSIS; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; RABBIT; STEATOSIS; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ALANINE TRANSAMINASE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ASPARTATE AMINOTRANSFERASES; BLOOD GLUCOSE; CHOLESTEROL, DIETARY; DISEASE MODELS, ANIMAL; FATTY LIVER; HEPATITIS; HYPERCHOLESTEROLEMIA; IMIDAZOLES; LIPIDS; LIVER; LIVER CIRRHOSIS; MALE; RABBITS; TETRAZOLES; TIME FACTORS;

EID: 79955536920     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.01.047     Document Type: Article

References (29)

1. Angulo P. Nonalcoholic fatty liver disease. Engl J Med 2002, 346(16):1221-1231.
2. Browning J.D., Szczepaniak L.S., Dobbins R., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40(6):1387-1395.
3. Clark J.M., Brancati F.L., Diehl A.M. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003, 98:960-967.
4. Bedogni G., Miglioli L., Masutti F., Tiribelli C., Marchesini G., Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the dionysos nutrition and liver study. Hepatology 2005, 42(1):44-52.
5. Kim W.R., Brown R.S., Terrault N.A., El-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology 2002, 36:227-242.
6. Angelico F., Burattin M., Alessandri C., Del Ben M., Lirussi F. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database Syst Rev 2007, (1):CD005166.
7. Angulo P., Hui J.M., Marchesini G., et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007, 45(4):846-854.
8. Farrell G.C., Larter C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006, 43(2 Suppl. 1):S99-S112.
9. Neuschwander-Tetri B.A., Caldwell S.H. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 2003, 37(5):1202-1219.
10. Lirussi F., Azzalini L., Orando S., Orlando R., Angelico F. Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev 2007, (1):CD004996.
11. Orlando R., Azzalini L., Orando S., Lirussi F. Bile acids for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev 2007, (January (1)):CD005160.
12. Bataller R., Gabele E., Schoonhoven R., et al. Prolonged infusion of angiotensin II into normal rats induces stellate cell activation and proinflammatory events in liver. Am J Physiol Gastrointest Liver Physiol 2003, 285(3):G642-G651.
13. Bataller R., Schwabe R.F., Choi Y.H., et al. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest 2003, 112(9):1383-1394.
14. Araki K., Masaki T., Katsuragi I., Tanaka K., Kakuma T., Yoshimatsu H. Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in diet-induced obese mice. Hypertension 2006, 48(1):51-57.
15. Sugimoto K., Qi N.R., Kazdová L., Pravenec M., Ogihara T., Kurtz T.M. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 2006, 47(5):1003-1009.
16. Yamamoto E., Dong Y.F., Kataoka K., et al. Olmesartan prevents cardiovascular injury and hepatic steatosis in obesity and diabetes, accompanied by apoptosis signal regulating kinase-1 inhibition. Hypertension 2008, 52(3):573-580.
17. Hirose A., Ono M., Saibara T., et al. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology 2007, 45(June (6)):1375-1381.
18. Benson S.C., Pershadsingh H.A., Ho C.I., et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension 2004, 43:993-1002.
19. Kleiner D.E., Brunt E.M., Van Natta M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41(6):1313-1321.
20. Zhou M.S., Schulman I.H. Prevention of diabetes in hypertensive patients: Results and implications from the VALUE trial. Vasc Health Risk Manag 2009, 5(1):361-368.
21. Henriksen E.J., Jacob S., Kinnick T.R., Teachey M.K., Krekler M. Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 2001, 38:884-890.
22. Higashiura K., Takada T., Li Y., et al. The effects of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist on insulin resistance in fructose-fed rats. Am J Hypertens 2000, 13:290-297.
23. Gillespie E.L., White C.M., Kardas M., Lindberg M., Coleman C.I. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care 2005, 28(9):2261-2266.
24. Yokohama S., Yoneda M., Haneda M., et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004, 40(5):1222-1225.
25. Kainuma M., Fujimoto M., Sekiya N., et al. Colesterol-fed rabbit as a unique model of nonalcoholic, nonobese, non-insulin-resistant fatty liver disease with characteristic fibrosis. J Gastroenterol 2006, 41(10):971-980.
26. Fujimoto M., Tsuneyama K., Kainuma M., et al. Evidence-based efficacy of Kampo formulas in a model of non alcoholic fatty liver. Exp Biol Med 2008, 233(3):328-337.
27. Otogawa K., Kinoshita K., Fujii H., et al. Erythrophagocytosis by liver macrophages (Kupffer cells) promotes oxidative stress, inflammation, and fibrosis in a rabbit model of steatohepatitis: implications for the pathogenesis of human nonalcoholic steatohepatitis. Am J Pathol 2007, 170(3):967-980.
28. Fu J.F., Fang Y.L., Liang L., Wang C.L., Hong F., Dong G.P. A rabbit model of pediatric nonalcoholic steatohepatitis: the role of adiponectin. World J Gastroenterol 2009, 15(8):912-918.
29. Tannock L.R., King V.L. Animal models of atherosclerosis: more than mice. Atherosclerosis 2010, 212(1):32-33.